FTISADTSK-$^{13}C_6$,$^{15}N_2$(TFA)

Cat. No.: HY-P3146S

Molecular Formula: $C_{38}{}^{13}C_6H_{69}F_3N_8{}^{15}N_2O_{18}$

Molecular Weight: 1091.01

Target: Isotope-Labeled Compounds

Pathway: Others

Storage: Sealed storage, away from moisture

Powder -80°C 2 years

-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (91.66 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.9166 mL	4.5829 mL	9.1658 mL
	5 mM	0.1833 mL	0.9166 mL	1.8332 mL
	10 mM	0.0917 mL	0.4583 mL	0.9166 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

FTISADTSK-$^{13}C_6$,$^{15}N_2$ TFA is ^{13}C- and ^{15}N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)[1][2].

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88(3):1871-1877.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-220.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA